BWXT Up 8% in a Week, But Analysts See 50% More to Go

BWX Technologies gained 8.4% over the past week to close at $137.93, outpacing the median 4.7% gain among its closest peers. Curtiss-Wright added 4.7%, Astronics rose 6.2%, and Woodward gained 3.3%. The week's standout in the group was FTAI Aviation, up 24%. At $137.93, BWXT trades roughly 33% below the consensus analyst price target of $207, a gap wide enough to capture most of the Street's attention ahead of the November 2 print.

That target gap is the central debate. JP Morgan cut its price target from $230 to $190 on October 13, retaining an Overweight rating, making it the most recent move from a bellwether firm. The broader analyst direction over the past month has been uniformly downward on targets: B of A Securities trimmed from $250 to $210, Northland cut from $250 to $220, and BNP Paribas moved from $190 to $165, though it kept a Neutral rating. Guggenheim and Jefferies, both initiating this autumn, set targets in the $181 to $192 range. The bull case rests on a backlog that has more than doubled to $8.4 billion since the end of 2023, with a 1.7x trailing twelve-month book-to-bill and roughly 73% backlog coverage over the next six quarters. Commercial Operations revenue has climbed from around $330 million in 2020 to above $1.1 billion in 2026. The bear case is simpler: at a P/E near 27 and an EV/EBITDA of 19.6, the stock prices in a lot of execution on mobile nuclear reactors and medical isotopes that has yet to materialise on the income statement.

The lending market offers no signal on directional conviction. Short interest of 3.8% of the free float is modest and moved up only 1.1% over the past week, while the borrow rate of 0.40% is low by any measure. Availability is extremely loose at over 4,000%, meaning there are vastly more shares available to borrow than are currently shorted. The options market tells a similar story: the put/call ratio of 0.25 is marginally below its 20-day average and well beneath the 52-week high of 0.57, pointing to no meaningful demand for downside protection ahead of the release. Neither shorts nor options traders are braced for a shock.

CEO Rex Geveden sold roughly $1.7 million in shares on August 12 under a pre-arranged 10b5-1 plan, so the transactions carry less signal than discretionary sales. Wikipedia attention for the stock is running about 1.5 standard deviations above its own 90-day norm, suggesting elevated retail interest into the event. The November 2 report will test whether management's 2026 guidance of approximately $3.80 billion in revenue and $345 million to $360 million in free cash flow is tracking, and whether the 2027 framework introduced alongside it is enough to close the distance between a $138 stock price and a $207 consensus target.